Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients

Seoul National University

Status: Withdrawn

Conditions: Autoimmune Encephalopathy

Treatments: Drug: Vigabatrin 500 MG

Study type: Interventional

Funder types: Other

Identifiers

NCT03003143

1607092776

Details and patient eligibility

About

Investigation of efficacy of vigabatrin in refractory autoimmune encephalitis patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18-85
• Possible autoimmune encephalitis
• Patients who have been diagnosed and treated for encephalitis for more than 4 weeks
• Patients with epilepsy (EEG finding or clinically)

Exclusion criteria

• septic shock, fever >38.5 ℃, O2 saturation <90%, respiratory rate >25, HR >120
• previously, mRS=3 or mRS>3
• MMSE<20
• Patients who have terminal disease
• eye problem
• pregnancy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Vigabatrin treatment group

Experimental group

Treatment:

Drug: Vigabatrin 500 MG